Figure 3.
The proposed positioning of lorlatinib in the treatment of ALK-positive patients with NSCLC.
Abbreviations: ALK, anaplastic lymphoma kinase; NSCLC, non-small cell lung cancer.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.